Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions

@inproceedings{Lee2016MolecularTT,
  title={Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions},
  author={Dae-Won Lee and Kyung-Hun Lee and Jin Wook Kim and Bhumsuk Keam},
  booktitle={International journal of molecular sciences},
  year={2016}
}
Leptomeningeal carcinomatosis (LMC) is the multifocal seeding of cerebrospinal fluid and leptomeninges by malignant cells. The incidence of LMC is approximately 5% in patients with malignant tumors overall and the rate is increasing due to increasing survival time of cancer patients. Eradication of the disease is not yet possible, so the treatment goals of LMC are to improve neurologic symptoms and to prolong survival. A standard treatment for LMC has not been established due to low incidences… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 96 references

Leptomeningeal metastases in the MRI era.

Neurology • 2011
View 4 Excerpts
Highly Influenced

A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1987
View 4 Excerpts
Highly Influenced

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial

A. T. Shaw, L. Gandhi, +7 authors T Mekhail
Lancet Oncol • 2016

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016

Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from bloom, a phase I study

J.C.-H. Yang, D.-W. Kim, +7 authors M.-J. Ahn
In Proceeding of the Annual Meeting of the American Society of Clinical Oncology, • 2016

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM)

M.-J. Ahn, D.-W. Kim, +7 authors J.C.-H. Yang
In Proceeding of the Annual Meeting of the American Society of Clinical Oncology, • 2016

Similar Papers

Loading similar papers…